FDA Approves AstraZeneca’s Imfinzi for Endometrial Cancer
Company Announcements

FDA Approves AstraZeneca’s Imfinzi for Endometrial Cancer

AstraZeneca (GB:AZN) has released an update.

AstraZeneca’s drug Imfinzi, in combination with chemotherapy, has been approved by the FDA for the treatment of advanced or recurrent endometrial cancer with mismatch repair deficiency. The DUO-E Phase III trial demonstrated that this treatment significantly reduces the risk of disease progression or death by 58%. The approval marks a significant development in addressing the urgent need for new treatments in combating the fourth most common cancer in US women.

For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyLegend Biotech an attractive takeover target for biopharma, says Daiwa
TheFlyAstraZeneca completes acquisition of Amolyt Pharma
TipRanks UK Auto-Generated NewsdeskAstraZeneca Acquires Amolyt Pharma for $1.05 Billion
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!